Replies to post #164 on Esperion Therapeutics Inc (ESPR)

[BuckeyeMike]

ESPR: Bempedoic Acid CVOT 75% chance of success. Proven Mechanism, Clear Path to Approval; Team of Lipid Experts... Well Funded.

In June of 2015, Analyst's had PTs from JMP $177, UBS $140 & Barclays $150. When ESPR was trading $100+.

Bempedoic acid was safe & effective in statin-intolerant patients -20% of all w/ lipid disorder. That's the advantage


Esperion Benefit from Trump Administration?
https://www.forbes.com/forbes/welcome/?toURL=https://www.forbes.com/sites/matthewherper/2017/03/20/is-esperion-therapeutics-going-to-benefit-from-a-trump-fda/&refURL=https://t.co/DawlFX1ubm&referrer=https://t.co/DawlFX1ubm